Peer Christiansen

Employment

• Aarhus University VIP, Professor
  2026 - Present
• Aarhus University Hospital Professor
  1994 - Present

Education

• Aarhus University MD
  1980 - Present

Projects & Funding

Projects & funding information is unavailable.

Publications (259)

• A structural equation modeling framework for estimating symptom burden based on symptom clusters in cancer survivors
  Scientific Reports 2026 DOI: 10.1038/s41598-026-55933-8
  +Save
• Persistent Health Disparities Among Adult Cancer Survivors
  International Journal of Cancer 2026 DOI: 10.1002/ijc.70770
  +Save
• Generelle tværgående senfølger efter kræft og kræftbehandling
  Ugeskrift for Læger 2026 DOI: 10.61409/V01260017
  +Save
• Prevalence of concurrent severe self-reported late symptoms and functional limitations in cancer survivors: a cross-sectional study of sociodemographic, clinical, and lifestyle associations
  Supportive Care in Cancer 2026 DOI: 10.1007/s00520-026-10482-8
  +Save
• 17β-Hydroxysteroid dehydrogenases 1 and 2
  Breast Cancer Research 2025 DOI: 10.1186/s13058-025-02196-2
  +Save
• The mediating role of new morbidities on social inequality in mortality after curative cancer treatment
  British Journal of Cancer 2025 DOI: 10.1038/s41416-025-03225-9
  +Save
• Beyond the first cut
  Breast 2025 DOI: 10.1016/j.breast.2025.104587
  +Save
• External validation of a multivariable prediction model for positive resection margins in breast-conserving surgery
  BMC Research Notes 2025 DOI: 10.1186/s13104-025-07103-8
  +Save
• The association between body mass index and neoadjuvant chemotherapy response in patients with breast cancer
  Breast Cancer Research 2025 DOI: 10.1186/s13058-025-02083-w
  +Save
• The association between lymph node status and the tumor size in breast cancer – results from the Danish Breast Cancer Group (DBCG)
  Acta Oncologica 2025 DOI: 10.2340/1651-226X.2025.43380
  +Save
• Impact of postoperative complications and type 2 diabetes on breast cancer recurrence and mortality
  British Journal of Surgery 2025 DOI: 10.1093/bjs/znaf176
  +Save
• Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients
  Pharmacoepidemiology and Drug Safety 2025 DOI: 10.1002/pds.70157
  +Save
• HbA1c levels and breast cancer prognosis in women without diabetes
  BMC Cancer 2025 DOI: 10.1186/s12885-025-14121-z
  +Save
• Statin Therapy in Early Breast Cancer
  Clinical Epidemiology 2025 DOI: 10.2147/CLEP.S509873
  +Save
• Axillary clearance and chemotherapy rates in ER+HER2− breast cancer
  The Lancet Regional Health - Europe 2024 DOI: 10.1016/j.lanepe.2024.101083
  +Save
• Prediction of High Nodal Burden in Patients with Sentinel Node-Positive Luminal ERBB2-Negative Breast Cancer
  JAMA Surgery 2024 DOI: 10.1001/jamasurg.2024.3944
  +Save
• The Population-level Effect of Adjuvant Therapies on Breast Cancer Recurrence
  Epidemiology 2024 DOI: 10.1097/EDE.0000000000001753
  +Save
• Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment
  The Lancet Oncology 2024 DOI: 10.1016/S1470-2045(24)00350-4
  +Save
• Quality assessment of radiotherapy in the prospective randomized SENOMAC trial
  Radiotherapy and Oncology 2024 DOI: 10.1016/j.radonc.2024.110372
  +Save
• Circulating C-reactive protein levels as a prognostic biomarker in breast cancer across body mass index groups
  Scientific Reports 2024 DOI: 10.1038/s41598-024-64428-3
  +Save